- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06166836
KRAS G12C 돌연변이 고형 종양에서 IN10018과 결합된 D-1553의 안전성과 효능을 평가하기 위한 Ib/II상 연구
KRAS G12C 돌연변이가 있는 국소 진행성 또는 전이성 고형 종양이 있는 피험자를 대상으로 IN10018과 결합된 D-1553의 안전성, 내약성, 약동학 및 효능을 평가하기 위한 1b/II상 공개 라벨 연구
This is a phase 1b/II, open-label study to evaluate the safety, tolerability, pharmacokinetics and antitumor activities of D-1553 in combination with IN10018 in subjects with locally advanced or metastatic solid tumor with KRAS G12C mutation.
연구 개요
상세 설명
This study includes 2 phases: Phase Ib-Dose Escalation and Phase II-Dose Expansion. Phase Ib-Dose Escalation part will enroll at least 6 subjects to identify the safety and RP2D of D1553 in combination with IN10018 in KRAS G12C mutant solid tumors. Phase II-Dose Expansion part contains 3 cohorts with cohort A to enroll advanced colorectal cancer (CRC) with KRAS G12C mutation, cohort B to enroll advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation, and cohort C to enroll other advanced solid tumors with KRAS G12C mutation. Phase II study is to evaluate the safety and antitumor activities of D-1553 in combination with IN10018 in KRAS G12C mutant solid tumors. The sample size in each cohort is estimated per Simon's 2-stage design. In Cohort A, when Simon's 2-stage study achieved statistical hypothesis, an open-label, randomized study will be conducted for factorial analysis to evaluate the contribution of IN10018 in the combination regimen.
연구 유형
등록 (추정된)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 장소
-
-
-
Bengbu, 중국
- First Affiliated Hospital of Bengbu Medical College
-
Changsha, 중국
- Hunan Cancer Hospital
-
Fuzhou, 중국
- Fujian Cancer Hospital
-
Ganzhou, 중국
- First Affiliated Hospital of Gannan Medical University
-
Nanjing, 중국
- General Hospital Of Eastern Theater Command
-
Wuhan, 중국
- Renmin Hospital of Wuhan University
-
Xuzhou, 중국
- Xuzhou Central Hospital
-
Zhengzhou, 중국
- Henan Cancer Hospital
-
Zhengzhou, 중국
- The first Affiliated Hospital of Zhengzhou University
-
-
Zhejiang
-
Hangzhou, Zhejiang, 중국, 310005
- Zhejiang Cancer Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Men or women aged ≥ 18 years at the time of signing the informed consent form.
- Subjects with pathologically confirmed locally advanced or metastatic solid tumors.
- Confirmed positive KRAS G12C mutation in tumor tissue or other biospecimens (only for phase1b) containing cancer cells or DNA.
- Tumor types in different phases and cohorts: 1) Phase 1b: subjects with locally advanced or metastatic solid tumors who have progressed on or failed in standard therapy, and no standard treatment is available. 2) Phase II Cohort A: subjects with locally advanced or metastatic CRC. 3) Phase II Cohort B: subjects with locally advanced or metastatic NSCLC. 4) Phase 2 Cohort C: subjects with other locally advanced or metastatic solid tumors.
- Has measurable lesions at baseline according to RECIST 1.1 criteria.
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate bone marrow, liver, renal, and coagulation function within 7 days prior to the first dose.
Exclusion Criteria:
- Prior KRAS G12C inhibitors treatment.
- Have known symptoms of spinal cord compression, instable or symptomatic central nervous system (CNS) metastases, and/or carcinomatous meningitis.
- Have a history of stroke or other serious cerebrovascular diseases within 12 months prior to the first dose.
- Have had interstitial lung disease or any active infection requiring systemic treatment within 14 days prior to the first dose.
- Has a history of severe cardiovascular disease such as acute myocardial infarction, severe/unstable angina, QTc prolongation, or poorly controlled hypertension.
- Haven't recovered from toxicity due to prior antitumor therapy
- Pregnant or lactating women.
- Malignant neoplasms other than study disease within 5 years prior to enrollment.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Phase 1b-Dose Escalation Part
To evaluate the safety and Recommended Phase 2 dose (RP2D) of D-1553 in combination with IN10018 in previously-treated solid tumors. |
D1553 orally taken,600mg twice a day IN10018 orally taken once daily at approximately the same time each day
다른 이름들:
|
|
실험적: Phase II Cohort A-previously-treated CRC with KRAS G12C mutation(Treatmnt Group)
To evaluate the safety and antitumor efficacy of D-1553 in combination with IN10018 in previously-treated CRCs with KRAS G12C mutation. |
D1553 orally taken,600mg twice a day IN10018 orally taken once daily at approximately the same time each day
다른 이름들:
|
|
활성 비교기: Phase II Cohort A-previously-treated CRC with KRAS G12C mutation (Control Group)
To evaluate the safety and antitumor efficacy of D-1553 in previously-treated CRCs with KRAS G12C mutation. |
D1553 orally taken,600mg twice a day |
|
실험적: Phase II Cohort B-treatment-naïve or previously-treated NSCLC with KRAS G12C mutation
To evaluate the safety and antitumor efficacy of D-1553 in combination with IN10018 in advanced NSCLCs with KRAS G12C mutation. |
D1553 orally taken,600mg twice a day IN10018 orally taken once daily at approximately the same time each day
다른 이름들:
|
|
실험적: Phase II Cohort C-other previously-treated solid tumors with KRAS G12C mutation
To evaluate the safety and antitumor efficacy of D-1553 in combination with IN10018 in other solid tumors with KRAS G12C mutation |
D1553 orally taken,600mg twice a day IN10018 orally taken once daily at approximately the same time each day
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Recommended phase II dose (RP2D) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation
기간: Through study completion, approximately 3 years
|
Evaluate the number of patients with dose-limited toxicities (DLTs); Determine the RP2D of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation. |
Through study completion, approximately 3 years
|
|
Objective Response Rate (ORR) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation
기간: Through study completion, approximately 3 years
|
Defined as the proportion of subjects with complete response (CR) or partial response (PR). |
Through study completion, approximately 3 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-free Survival (PFS) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation
기간: Through study completion, approximately 3 years
|
Defined as the time from the first dose of study treatment to first documentation of disease progression or to death due to any cause, whichever comes first. |
Through study completion, approximately 3 years
|
|
Duration of Response (DoR) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation
기간: Through study completion, approximately 3 years
|
Defined as the time from start of the first documentation of CR or PR to the first documentation of disease progression or to death due to any cause, whichever comes first. |
Through study completion, approximately 3 years
|
|
Disease Control Rate (DCR) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation
기간: Through study completion, approximately 3 years
|
Defined as the proportion of patients with CR, PR, or stable disease (SD). |
Through study completion, approximately 3 years
|
|
Overall survival (OS) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation
기간: Through study completion, approximately 3 years
|
Defined as the time from the first dose of study treatment to the date of death due to any cause. |
Through study completion, approximately 3 years
|
|
Number of subjects with adverse event
기간: Through study completion, approximately 3 years
|
The number of subjects who experienced AEs is presented. |
Through study completion, approximately 3 years
|
|
Plasma concentrations of D-1553 and IN10018 in solid tumors with KRAS G12C mutation
기간: Through study completion, approximately 3 years
|
Plasma concentrations of D-1553 and IN10018 |
Through study completion, approximately 3 years
|
|
PK: Cmax of D-1553 and IN10018
기간: Through study completion, approximately 3 years
|
Maximum concentration (Cmax) |
Through study completion, approximately 3 years
|
|
PK: Cmin of D-1553 and IN10018
기간: Through study completion, approximately 3 years
|
Minimum concentration (Cmin) |
Through study completion, approximately 3 years
|
|
PK:t1/2 of D-1553 and IN10018
기간: Through study completion, approximately 3 years
|
Elimination half-life (t1/2). |
Through study completion, approximately 3 years
|
|
PK:CL/F of D-1553 and IN10018
기간: Through study completion, approximately 3 years
|
apparent clearance (CL/F) |
Through study completion, approximately 3 years
|
|
PK:Vd/F of D-1553 and IN10018
기간: Through study completion, approximately 3 years
|
Apparent volume of distribution (Vd/F) |
Through study completion, approximately 3 years
|
|
PK: AUC of D-1553 and IN10018
기간: Through study completion, approximately 3 years
|
Area under the concentration-time curve (AUC) |
Through study completion, approximately 3 years
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Zhengbo Song, Study Principal Investigator
간행물 및 유용한 링크
일반 간행물
- Song Z, Li X, Lin R, Shi H, Yuan Y, Liu Y, Luo Y, Lv T, Zhang Y, Zhu L, Zhu Y, Zhang L, Wang Z. Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial. Lancet Respir Med. 2026 Jul 7:S2213-2600(26)00142-6. doi: 10.1016/S2213-2600(26)00142-6. Online ahead of print.
- Song Z, Zhu L, Liu Y, Lin R, Li X, Luo Y, Yuan Y, Shi H, Zhang Y, Zhang B, Zhu Y, Wang Z, Cheng X. Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial. Lancet Oncol. 2026 Sep;27(9):1133-1145. doi: 10.1016/S1470-2045(26)00175-0.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- D1553-106/IN10018-602
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .